Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma.
Davids
Matthew S
MS
Department of Haematology/Oncology, National University Health System, Singapore, Singapore.
Davids
Matthew
M
Charlton
Amanda
A
Ng
Swee-Siang
SS
Chong
Mei-Ling
ML
Laubscher
Kevin
K
Dar
Mohammed
M
Hodge
Jeffrey
J
Soong
Richie
R
Goh
Boon Cher
BC
D000368:Aged; D001483:Base Sequence; D015415:Biomarkers / Q000378:metabolism; D015266:Carcinoma, Merkel Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D004252:DNA Mutational Analysis; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007191:Indazoles; D007633:Keratins / Q000378:metabolism; D009154:Mutation; D009362:Neoplasm Metastasis; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics; D012535:Scalp; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D013449:Sulfonamides / Q000627:therapeutic use*
D015415:Biomarkers; C400901:CAM 5.2 antigen; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D007633:Keratins; C516667:pazopanib; D020796:Receptor, Platelet-Derived Growth Factor alpha; D010751:Phosphopyruvate Hydratase